Bertrand Cariou

Inhibition of insulin receptor catalytic activity by the molecular adapter Grb14.

The adapter protein ZIP binds Grb14 and regulates its inhibitory action on insulin signaling by recruiting protein kinase Czeta.

Inhibition of FGF receptor signalling in Xenopus oocytes: differential effect of Grb7, Grb10 and Grb14.

Cellular and molecular mechanisms of adipose tissue plasticity in muscle insulin receptor knockout mice.

Regulation and functional roles of Grb14.

Increased adipose tissue expression of Grb14 in several models of insulin resistance.

Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties.

Farnesoid X receptor: a new player in glucose metabolism?

Potential regulatory role of the farnesoid X receptor in the metabolic syndrome.

The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition.

Transient impairment of the adaptive response to fasting in FXR-deficient mice.

Feasibility and benefit of fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases.

Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c.

The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice.

The expanding role of the bile acid receptor FXR in the small intestine.

FXR: More than a bile acid receptor?

FXR: a promising target for the metabolic syndrome?

FXR-deficiency confers increased susceptibility to torpor.

Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.

Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes.

PCSK9 and LDL cholesterol: unravelling the target to design the bullet.

Role of bile acids and bile acid receptors in metabolic regulation.

Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia.

A corticotroph pituitary adenoma as the initial presentation of familial glucocorticoid deficiency.

High protein intake reduces intrahepatocellular lipid deposition in humans.

PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.

PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.

[Cholesterol metabolism and beta-cell function].

Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients.

The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways.

[Dyslipidemia].

Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity.

Clinical aspects of PCSK9.

Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults.

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.

Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.

[Management of hypercholesterolemia: what target for LDL cholesterol?].

DPP-4 inhibitors in the treatment of type 2 diabetes.

Thiazolidinediones and PPARγ agonists: time for a reassessment.

Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).

New avenues for the pharmacological management of type 2 diabetes: an update.

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets.

Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury.

Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes.

Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.

Function of seipin: new insights from Bscl2/seipin knockout mouse models.

A standardized vascular disease health check in europe: a cost-effectiveness analysis.

Surgery for 'asymptomatic' mild primary hyperparathyroidism improves some clinical symptoms postoperatively.

Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism.

Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.

[Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].

Congenital lipodystrophies and dyslipidemias.

Preserved adrenal function in fully PCSK9-deficient subject.

GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.

The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.

Long-term effects of Roux-en-Y gastric bypass on postprandial plasma lipid and bile acids kinetics in female non diabetic subjects: A cross-sectional pilot study.

[Trans-intestinal cholesterol excretion (TICE): a new route for cholesterol excretion].

[Hormonal evaluation of adrenal incidentalomas].

PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension.

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.

Management of thyroid nodules incidentally discovered on MIBI scanning for primary hyperparathyroidism.

Laparoscopic Gastric Banding in Obese Patients with Sleep Apnea: A 3-Year Controlled Study and Follow-up After 10 Years.

Role of PCSK9 beyond liver involvement.

Letter from Le May and Cariou regarding article, "Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms".

Clinical use of insulin degludec.

The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.

Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels.

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.

mTOR inhibitors and diabetes.

Vitamin D deficiency is an independent risk factor for PTDM after kidney transplantation.

Death, end-stage renal disease and renal function decline in patients with diabetic nephropathy in French cohorts of type 1 and type 2 diabetes.

Sotagliflozin as a potential treatment for type 2 diabetes mellitus.

Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.

PCSK9 Inhibition: Does Lipoprotein Size Matter?

[A YOUNG MAN WHOSE LDL-CHOLESTEROL IS GREATER THAN 1.9 G/L].

Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.

Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.

Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.

FGF21 Improves the Adipocyte Dysfunction Related to Seipin Deficiency.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials.

PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering.

Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes.

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.

Severely uncontrolled diabetes: a new aetiology of acquired bisalbuminaemia.

EGF-A peptides: A promising strategy for PCSK9 inhibition.

Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes.

Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes.

Association between sleep disturbances, fear of hypoglycemia and psychological well-being in adults with type 1 diabetes mellitus, data from cross-sectional VARDIA study.

Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes.

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.

Correction to: Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.

Euglycaemic ketoacidosis during gestational diabetes with concomitant COVID-19 infection.

Comment on Chen et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care 2020;43:1399-1407.

Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study.

Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: Results from the CORONADO study.

Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study.

Impact of parathyroidectomy on cardiovascular risk in primary hyperparathyroidism: A narrative review.

PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs.

Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes.

Transintestinal cholesterol excretion in health and disease.

COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study.

Generation of a GPR146 knockout human induced pluripotent stem cell line (ITXi001-A-1).

CRISPR-Cas9 Engineering in Hypobetalipoproteinemia: A Promising Tool for Functional Studies of Novel Variants.

Nutritional biomarkers and heart failure requiring hospitalization in patients with type 2 diabetes: the SURDIAGENE cohort.

Impact of diabetes on COVID-19 prognosis beyond comorbidity burden: the CORONADO initiative.

Identification of a Gain-of-Function Variant as a Novel Cause of Familial Combined Hypocholesterolemia.

PCSK9 deficiency results in a specific shedding of excess LDLR in female mice only: Role of hepatic cholesterol.

Effect of the LDL receptor mutation type on incident major adverse cardiovascular events in familial hypercholesterolaemia.

Variants in the Gene Are Associated With a Favorable Cardiometabolic Risk Profile.

Associations of microvascular complications with all-cause death in patients with diabetes and COVID-19: The CORONADO, ABCD COVID-19 UK national audit and AMERICADO study groups.

FACS-assisted CRISPR-Cas9 genome editing of human induced pluripotent stem cells.

Effects of parathyroidectomy on kidney function in patients with primary hyperparathyroidism: Results of a prospective study.

Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans: A prospective cohort study.

Renal function decline and heart failure hospitalisation in patients with type 2 diabetes: Dynamic predictions from the prospective SURDIAGENE cohort.

A new 165-SNP low-density lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia.

Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: Insights from the ODYSSEY APPRISE study.

Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort.